• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Director Rigaud Olivier was granted 980 shares, increasing direct ownership by 181% to 1,520 units (SEC Form 4)

    4/11/25 5:04:27 PM ET
    $BCPC
    Major Chemicals
    Industrials
    Get the next $BCPC alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rigaud Olivier

    (Last) (First) (Middle)
    C/O BALCHEM CORPORATION
    5 PARAGON DRIVE

    (Street)
    MONTVALE NJ 07645

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BALCHEM CORP [ BCPC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    02/14/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/12/2025 A 980(1) A $0 1,520 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Ownership of restricted stock vests in Reporting Person 1 year following the grant date, subject to restriction of transfer in accordance with the provisions of the Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
    Remarks:
    This Form 4/A amends and restates the original Form 4 filed on February 14, 2025, which inadvertently noted the vesting period as 3 years from the grant date, instead of 1 year.
    /s/ Travis Larsen, Attorney in Fact for Olivier Rigaud 04/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCPC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCPC

    DatePrice TargetRatingAnalyst
    3/8/2022$170.00 → $155.00Buy
    HC Wainwright & Co.
    2/22/2022$175.00Neutral → Buy
    Sidoti
    1/10/2022$160.00 → $170.00Buy
    HC Wainwright & Co.
    11/29/2021$175.00Buy → Neutral
    Sidoti
    8/2/2021$140.00 → $145.00Overweight → Equal-Weight
    Stephens & Co.
    8/2/2021$145.00 → $160.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCPC
    SEC Filings

    View All

    SEC Form 10-Q filed by Balchem Corporation

    10-Q - BALCHEM CORP (0000009326) (Filer)

    7/31/25 4:17:29 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BALCHEM CORP (0000009326) (Filer)

    7/31/25 7:17:48 AM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form 11-K filed by Balchem Corporation

    11-K - BALCHEM CORP (0000009326) (Filer)

    6/24/25 4:38:30 PM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Balchem Corporation Reports Second Quarter 2025 Financial Results

    MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor

    7/31/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

    MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch

    7/17/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation to Present at the CJS Annual New Ideas Summer Conference on July 10, 2025

    MONTVALE, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the CJS Annual New Ideas Summer Conference on July 10, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest qual

    6/26/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BCPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EVP, CLO, & Secretary Miyata Hatsuki covered exercise/tax liability with 483 shares, decreasing direct ownership by 7% to 6,189 units (SEC Form 4)

    4 - BALCHEM CORP (0000009326) (Issuer)

    7/28/25 6:15:00 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SVP and GM, Specialty Products Van Gunsteren Job Leonard was granted 2,128 shares and covered exercise/tax liability with 964 shares, increasing direct ownership by 14% to 9,446 units (SEC Form 4)

    4/A - BALCHEM CORP (0000009326) (Issuer)

    4/11/25 7:11:10 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SVP & Chief HR Officer Tignor Michael Brent was granted 3,497 shares and covered exercise/tax liability with 1,156 shares, increasing direct ownership by 35% to 9,123 units (SEC Form 4)

    4/A - BALCHEM CORP (0000009326) (Issuer)

    4/11/25 6:43:35 PM ET
    $BCPC
    Major Chemicals
    Industrials

    HC Wainwright & Co. reiterated coverage on Balchem with a new price target

    HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously

    3/8/22 6:19:56 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem upgraded by Sidoti with a new price target

    Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00

    2/22/22 8:56:13 AM ET
    $BCPC
    Major Chemicals
    Industrials

    HC Wainwright & Co. reiterated coverage on Balchem with a new price target

    HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously

    1/10/22 6:15:56 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Leadership Updates

    Live Leadership Updates

    View All

    AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

    BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

    8/16/21 8:00:00 AM ET
    $AZRX
    $BCPC
    $BDSI
    Major Pharmaceuticals
    Health Care
    Major Chemicals
    Industrials

    $BCPC
    Financials

    Live finance-specific insights

    View All

    Balchem Corporation Reports Second Quarter 2025 Financial Results

    MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor

    7/31/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

    MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch

    7/17/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Reports First Quarter 2025 Financial Results

    MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o

    4/24/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Balchem Corporation

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    11/13/24 6:56:07 PM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    2/13/24 4:59:02 PM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    2/9/24 11:29:17 AM ET
    $BCPC
    Major Chemicals
    Industrials